---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000457"
form_type: "8-K"
ticker: "BYSI"
cik: "0001677940"
company_name: "BeyondSpring Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:24:14.870196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BeyondSpring sells SEED Therapeutics stake for $35.4M to fund Plinabulin trials

## Summary
- Sells 8,333,637 Series A-1 Preferred Shares at $4.25/share to three investors for ~$35.4M gross proceeds.
- After all closings, BeyondSpring and subsidiary will own ~14.4% of SEED (down from ~41% initially).
- Proceeds advance Plinabulin to registrational studies; DUBLIN-3 showed OS benefit in NSCLC.
- 303 study of Plinabulin + pembrolizumab/docetaxel achieved 89.3% DCR and 8.6 mo median PFS.
- 302 study enrolling first-line ES-SCLC patients; Plinabulin has GEF-H1 immune activation mechanism.

## SEC filing metadata
- accession: 0001171843-25-000457
- form_type: 8-K
- ticker: BYSI
- cik: 0001677940
- company_name: BeyondSpring Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677940/000117184325000457/0001171843-25-000457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677940/000117184325000457/f8k_012725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000457
- JSON: https://secwatch.observer/filing/0001171843-25-000457.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000457.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.